Suppr超能文献

STING 信号在黑色素瘤细胞中的作用影响其抗原性,并能促进抗肿瘤 T 细胞活性。

STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.

机构信息

Immunology Program, Moffitt Cancer Center, Tampa, Florida.

Cutaneous Oncology Program, Moffitt Cancer Center, Tampa, Florida.

出版信息

Cancer Immunol Res. 2019 Nov;7(11):1837-1848. doi: 10.1158/2326-6066.CIR-19-0229. Epub 2019 Aug 28.

Abstract

STING (stimulator of IFN genes) signaling is an innate immune pathway for induction of a spontaneous antitumor T-cell response against certain immunogenic tumors. Although antigen-presenting cells are known to be involved in this process, insight into the participation of tumor cell-intrinsic STING signaling remains weak. In this study, we find diversity in the regulation of STING signaling across a panel of human melanoma cell lines. We show that intact activation of STING signaling in a subset of human melanoma cell lines enhances both their antigenicity and susceptibility to lysis by human melanoma tumor-infiltrating lymphocytes (TIL) through the augmentation of MHC class I expression. Conversely, defects in the STING signaling pathway protect melanoma cells from increased immune recognition by TILs and limit their sensitivity to TIL lysis. Based on these findings, we propose that defects in tumor cell-intrinsic STING signaling can mediate not only tumor immune evasion but also resistance to TIL-based immunotherapies.

摘要

STING(干扰素基因刺激物)信号是诱导针对某些免疫原性肿瘤的自发抗肿瘤 T 细胞反应的先天免疫途径。尽管已知抗原呈递细胞参与了这一过程,但对肿瘤细胞内在的 STING 信号的参与仍知之甚少。在这项研究中,我们发现了一系列人黑色素瘤细胞系中 STING 信号调节的多样性。我们表明,在人类黑色素瘤细胞系的亚群中,完整的 STING 信号激活通过增强 MHC Ⅰ类表达,增强了它们的抗原性和对人类黑色素瘤肿瘤浸润淋巴细胞(TIL)的溶解敏感性。相反,STING 信号通路的缺陷可保护黑色素瘤细胞免受 TIL 增强的免疫识别,并限制其对 TIL 溶解的敏感性。基于这些发现,我们提出肿瘤细胞内在的 STING 信号缺陷不仅可以介导肿瘤免疫逃逸,还可以抵抗基于 TIL 的免疫疗法。

相似文献

1
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.
Cancer Immunol Res. 2019 Nov;7(11):1837-1848. doi: 10.1158/2326-6066.CIR-19-0229. Epub 2019 Aug 28.
4
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13. doi: 10.1073/pnas.1512832112. Epub 2015 Nov 25.
10
Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.
Clin Cancer Res. 2016 May 1;22(9):2237-49. doi: 10.1158/1078-0432.CCR-15-2294. Epub 2015 Dec 28.

引用本文的文献

2
Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges.
BMJ Oncol. 2025 Aug 4;4(1):e000566. doi: 10.1136/bmjonc-2024-000566. eCollection 2025.
4
A versatile immunomodulated nanoCRISPR converter augments the susceptibility and visibility of tumors to the immune system.
Proc Natl Acad Sci U S A. 2025 Jul 22;122(29):e2415100122. doi: 10.1073/pnas.2415100122. Epub 2025 Jul 15.
6
Carriers Multimerize STING Protein Fragments to Activate Type I Interferon Signaling in STING-Deficient Cancer Cells.
Mol Pharm. 2025 Aug 4;22(8):4632-4650. doi: 10.1021/acs.molpharmaceut.5c00226. Epub 2025 Jul 6.
7
Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release.
J Immunother Cancer. 2025 Apr 29;13(4):e010889. doi: 10.1136/jitc-2024-010889.
8
Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy.
Arch Dermatol Res. 2025 Apr 19;317(1):729. doi: 10.1007/s00403-025-04237-4.
9
cGAS-STING signaling in melanoma: regulation and therapeutic targeting.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 14. doi: 10.1007/s00210-025-04141-8.

本文引用的文献

1
Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line.
Front Immunol. 2018 Jul 16;9:1609. doi: 10.3389/fimmu.2018.01609. eCollection 2018.
2
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Sci Transl Med. 2018 Jul 18;10(450). doi: 10.1126/scitranslmed.aar3342.
3
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
4
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
5
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
Cancer Res. 2016 Nov 15;76(22):6747-6759. doi: 10.1158/0008-5472.CAN-16-1404. Epub 2016 Sep 28.
6
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing.
Nat Immunol. 2016 Sep 20;17(10):1142-9. doi: 10.1038/ni.3558.
7
The host STING pathway at the interface of cancer and immunity.
J Clin Invest. 2016 Jul 1;126(7):2404-11. doi: 10.1172/JCI86892.
8
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Immunity. 2016 Jun 21;44(6):1255-69. doi: 10.1016/j.immuni.2016.06.001.
9
The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells.
Immunity. 2016 May 17;44(5):1177-89. doi: 10.1016/j.immuni.2016.04.010. Epub 2016 May 10.
10
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Nat Rev Cancer. 2016 May;16(5):275-87. doi: 10.1038/nrc.2016.36. Epub 2016 Apr 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验